Rosario Dueñas, MD

Articles by Rosario Dueñas, MD

Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer

ByPedro Sánchez-Rovira, MD, PhD,Ana Jaén, MD,Encarna González, MD,Ignacio Porras, MD,Rosario Dueñas, MD,Begoña Medina, MD,Nicolás Mohedano, MD,Margarita Fernández, MD,Maximiliano Martos, MD,Ana Lozano, MD,Eva Carrasco, MD

February 1st 2001

In a single-center, open, phase II trial, we assessed the toxicity and activity of a triple combination therapy-doxorubicin at 30 mg/m2 (day 1), paclitaxel (Taxol) at 135 mg/m2 (day 2), and gemcitabine (Gemzar) at 2,500 mg/m2

Latest Updated Articles

Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer
Published: February 1st 2001 | Updated:

Rosario Dueñas, MD

Articles by Rosario Dueñas, MD

Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma

CD20 Bispecifics vs CAR T: Evaluating CRS and ICANS in Lymphoma

KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs